BlackRock Health Sciences Trust II (BMEZ)
NYSE 
BMEZ: Removal Of Options Should Improve Performance (Rating Upgrade)
BlackRock Health Sciences Trust II offers exposure to healthcare innovation but faces NAV instability and dividend sustainability concerns. BMEZ's strategy targets high-growth healthcare sectors, leveraging BlackRock's expertise, yet recent performance highlights volatility and risk to distributions. Potential growth in healthcare is supported by industry trends, but BMEZ's NAV fluctuations and payout risks warrant close monitoring.
BMEZ: Sell, Distributions Down 34% And Undercovered
BlackRock Health Sciences Trust II yields 9.59% but has reduced its monthly payout by 34% to $0.11. BMEZ's NAV and net assets have declined sharply, with net assets dropping 44% over two years and persistent underperformance versus sector peers. Distributions are mostly return of capital (75%), offering tax deferral but eroding investor basis; distribution coverage remains weak at 0.38x.
Forget Software Stocks: This 8.8% Dividend Is The Real AI Bargain
Wall Street is mired in another panic over AI. And we contrarians are here for it.
BMEZ: Deep Discount Once Again Makes It An Interesting Play
BlackRock Health Sciences Term Trust (BMEZ) now trades at a compelling 12% discount, offering a potential entry for investors seeking relatively volatile healthcare exposure. BMEZ removed its options writing strategy, increasing reliance on capital appreciation from its biotech-tilted, growth-oriented portfolio for both returns and distribution coverage. The fund's distribution was cut from a 12% managed rate to a more sustainable payout level, with payouts primarily reliant on capital gains rather than income.
BMEZ: NAV Decline Continues And Underperforms Peers
BlackRock Health Sciences Term Trust continues to struggle with unsustainable distributions and rapid NAV decline, prompting a maintained Sell rating. BMEZ's high 8.4% yield is not supported by net investment income, leading to persistent NAV erosion and reliance on return of capital. Despite broad healthcare exposure and option strategies, BMEZ underperforms peers like THQ and BME in total return and capital preservation.
A Dividend Cut Just Created A 9.2% Monthly Dividend Bargain
Most Wall Street “suits” are allergic to dividend cuts. These spreadsheet jockeys sooooo lack imagination.
BMEZ: This Healthcare Fund Is Paying Out More Than It Earns
BlackRock Health Sciences Term Trust (BMEZ) exposes investors to life science companies but the performance has been flawed since inception. The fund writes options against its holdings, which helps amplify income levels but makes it difficult for the fund to participate in capital appreciation. BMEZ offers a high dividend yield of 14.2% but the fund is paying out more than it actually earns.
Why I Moved On From BMEZ Despite A 14.2% Yield (Rating Downgrade)
BlackRock Health Sciences Term Trust's discount to NAV has narrowed sharply, eroding the original deep-value thesis and making the risk/reward profile less attractive. BlackRock's tender offer and increased distributions successfully closed the discount, but future activist pressure is now limited due to Saba's standstill agreement. The fund's high 14% yield is appealing but unsustainable, as it relies on return of capital rather than underlying earnings, especially in biotech.
BMEZ: Recession Fears Making You Sick? Buy This High-Yield Healthcare Fund
Fear of a looming recession has investors seeking defensive sectors like Healthcare, which benefits from positive secular trends and offers high-yield dividend stocks. The BlackRock Health Sciences Term Trust provides high-yield income through healthcare equities and an option writing strategy, with a current distribution rate of 13.6%. BMEZ's top holdings, including Intuitive Surgical, argenx SE, and Alnylam Pharmaceuticals, show strong growth potential, despite past underperformance due to market conditions.
BMEZ: 12% Discount, High Yield On Healthcare Monthly Payer
BMEZ employs an option writing strategy and has a 12-year limited term, with a recent increase in monthly distributions to 12% of NAV. This article details BMEZ's top holdings, sector and geographic exposure and changes in 2024. Dividend yield, earnings, taxes, expenses, and average volume are also covered.
BMEZ: Remains Attractive With A Deep Discount
BMEZ offers a more speculative but attractive healthcare investment with significant biotech exposure, mid-cap, small-cap, and private investments. The fund's discount remains appealing, that is despite narrowing from around 18% to ~10% from the start of the year. The fund has employed a 12% managed distribution as well as being one of the several BlackRock funds to have a discount management program in place.
BMEZ: A 14.2% Yielding CEF With An 11.85% Discount And Activist Pressure
BMEZ trades at an 11.85% discount to NAV, offering a high distribution rate of 14.2% annually, despite high fees and management concerns. The fund focuses on healthcare and technology, with 8.3% in private investments, and employs a call-selling strategy on 23% of its holdings. Activist pressure from Saba Capital and others could lead to future measures like distribution increases, fee reductions, or management changes.
